Open access
Sep 2026
Biohybrid nanovesicle-mediated targeted delivery of HSP90 inhibitor for enhanced sorafenib therapy of hepatocellular carcinoma after radiofrequency ablation
Hepatocellular carcinoma (HCC) presents significant therapeutic challenges due to enhanced liver cancer stem cell (LCSC) stemness and sorafenib resistance after radiofrequency ablation (RFA). To address these limitations, biohybrid nanovesicles (hNVs) are prepared by fusing milk-derived exosomes with sorafenib-resistan...
Ang-Feng Jiang, Xian-Fei Zhou, Jin-Chao Zhao et al.
· Materials Today Bio · 0 citations